Kathleen Raven

Kathleen Raven

Kathleen Raven reports on cutting-edge solid tumor cancer drug developments and clinical trials for BioPharm Insight, owned by The Financial Times Group, in New York City. She’s previously written for Reuters Health, Scientific American, MATTER, Nature Medicine and other U.S. publications. She has been a recipient of the following short-term reporting fellowships: National Academies Keck Futures Initiative, Goethe Institute, Fulbright Berlin Capital and Falling Walls. She has two master’s degrees from the University of Georgia in Ecology and Health & Medical Journalism.

Posts: